Drug Profile
Peroxovanadium compounds
Latest Information Update: 15 Jun 2001
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antihyperglycaemics
- Mechanism of Action Protein-tyrosine-phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Parasitic infections